UNSPSC 51172117: Aseripide

This classification denotes an antispasmotic agent with the molecular formula C26H30FN3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2M24F1I2A, chemically known as (2r,4r)-3-(n-((3-((s)-1-carboxyethyl)phenyl)carbamoyl)glycyl)-2-(o-fluorophenyl)-4-thiazolidinecarboxylic acid, 4-tert-butylester but generally known as aseripide, which bears US NIH Compound Identifier 179339. European Medicines Agency schedules Aseripide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05580MIG.

UNSPSC 51172117 Aseripide, a Commodity code, represents pharmaceutical and therapeutic products acquired by state and local jurisdictions for clinical, correctional, and public health programs. Recent state and local solicitations under this code show procurement of generic multi-source pharmaceuticals, over-the-counter products, and specialized testing pharmaceuticals—spanning from bulk pharmaceutical distribution through authorized wholesalers to offender drug-testing services requiring immunoassay and confirmatory testing methodologies. State health and human services agencies, county correction departments, and cooperative purchasing alliances drive the activity; the Texas Health and Human Services Commission, Collin County Community Supervision and Corrections Department, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear among recent buyers.

Texas and Minnesota show the strongest recent activity under this code. The Minnesota Department of Administration issued an RFP through MMCAP for generic multi-source pharmaceuticals and OTC products (response deadline March 26, 2026) to supply state and local facilities across multiple jurisdictions including Oregon; the contract spans two years with optional extensions through June 30, 2028, and pricing is weighted heavily toward competitiveness (75 percent of evaluation), with compliance, administrative fees, and EDI capability comprising the remainder. Collin County (Texas) released an RFP for offender specimen collection and drug testing services (due July 23, 2026) valued at $600,000 annually, encompassing staffing, lab certification, immunoassay screening with LC/MS/MS or GC/MS confirmation, and electronic reporting across two collection sites—a two-year base with up to three optional one-year renewals. The Texas Health and Human Services Commission concurrently issued an RFI on therapeutic pharmacy initiative direct-to-manufacturer prescriptions (April 2026) to gather vendor capabilities for future direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels, signaling exploratory state-level interest in alternative pharmaceutical procurement models.